semaglutide patent expiry europe Last week's of the for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions The US and European patents

This makes the pair a logical combination for sports nutrition and active-lifestyle formulas, but the claim language should remain structure/function-oriented rather than disease- or fat-loss-cure oriented

The main additional consideration: MT-II should not be used during pregnancy or breastfeeding due to insufficient safety data

These usually occur after a trauma as a consequence of blood extravasation into the soft tissues or spontaneously because of some defect in the hemostatic mechanism, such as idiopathic thrombocytopenic purpura

However, both medications elevate cardiovascular stress markersheart rate, blood pressure, and sympathetic tonecreating a compounding risk profile that most prescribers avoid

These advances highlight a transition towards individualized, technology-enhanced diabetes management, ensuring better results for patients globally [5]

1,2 Emagrecimento e agonistas do GLP-1 A combinao entre restrio calrica e aumento da atividade fsica continua sendo a base das estratgias convencionais para perda de peso, trazendo uma srie de benefcios importantes para a sade metablica